

- Human papillomavirus (HPV) infections, **1197**  
 anal cancer and, 544, 1198  
 cervical cancer and  
   mechanisms of, 101e-7, 214e-7  
   risk factors for, 351, 595  
   types associated with, 595, 1198  
 clinical features of, 1198–1199, 1199f  
 counseling for, 1201  
 diagnosis of, 150e-7  
 epidemiology of, 1198  
 global considerations in, 595, 1198  
 in HIV infection, 1271–1272  
 HIV infection and, 1198  
 immune response to, 1198  
 incidence of, 869  
 oropharyngeal cancer and, 477, 502, 505, 1198  
 pathogenesis of, 1197–1198  
 in pregnancy, 124e-2  
 prevention of, 1200, 1201. *See also* Human papillomavirus (HPV) vaccine  
 in transplant recipient, 926  
 treatment of, 1200–1201, 1201t  
 warts, 240t, 351, 829, 1198, 1199f
- Human papillomavirus (HPV) vaccine  
 for anogenital wart prevention, 351  
 bivalent, 1199–1200  
 for cervical cancer prevention, 595  
 contraindications to, 789t  
 cross-protection from, 1200  
 effectiveness of, 476–477  
 precautions for, 789t  
 quadrivalent, 1200  
 recommended administration of  
   in adults, 29t, 787f, 788f, 883  
   in children and adolescents, 883, 1200  
   in HIV infection, 1253t  
   in transplant recipient, 929t  
 second-generation, 1200  
 virus-like particles in, 1199
- Human respiratory syncytial virus (HRSV), 1205
- Human respiratory syncytial virus (HRSV) infections, **1205**  
 in cancer patient, 489, 492  
 clinical features of, 225, 229, 234, 1202t, 1206  
 diagnosis of, 1206  
 epidemiology of, 1205  
 health care–associated, 1205  
 in immunocompromised patient, 1205  
 pathogenesis of, 1205–1206  
 prevention of, 1206  
 in transplant recipient, 923  
 treatment of, 215e-2t, 1206
- Human stem cell leukemic-lymphoma syndrome. *See* *FGFR1*-mutated eosinophilia
- Human T-cell lymphotropic virus (HTLV-1) carcinogenicity of, 477t  
 discovery of, 225e-2–3  
 gene expression and regulation in, 214e-5  
 molecular biology of, 225e-3–4  
 structure of, 225e-1–2, 225e-3f
- Human T-cell lymphotropic virus-1 (HTLV-1) infections  
 adult T-cell leukemia/lymphoma. *See* Adult T-cell leukemia/lymphoma  
 arthritis syndromes in, 837  
 clinical features of, 152e-6t  
 epidemiology of, 152e-6t, 225e-4, 225e-4f  
 global considerations in, 225e-4, 225e-4f  
 lymphoid malignancies, 697  
 myelopathy, 163, 225e-5, 697, 707, 2657  
 prevention of, 225e-5  
 in returning war veterans, 152e-6t  
 transfusion-transmitted, 138e-3t, 138e-6  
 treatment of, 225e-5
- Human T-cell lymphotropic virus-2 (HTLV-2) infections, 225e-5–6
- Humidifier fever, 1681t  
 “Hummingbird sign,” 2610
- Humoral hypercalcemia of malignancy, 2476.  
*See also* Hypercalcemia, malignancy-associated
- Hunger, 415e-2  
 Hunner’s lesion, 60e-1  
 Hunter disease, 432e-2t, 432e-6  
 Hunt-Hess scale, for subarachnoid hemorrhage, 1785t
- Huntingtin, 453e-6, 2621–2622
- Huntington’s disease, **2621**  
 clinical features of, 163, 184, 2606, 2621  
 etiology of, 2621–2622  
 functional anatomy of, 170  
 genetic considerations in, 434, 440, 440t, 444e-9, 2621–2622  
 genetic testing for, 448  
 imaging in, 441e-23f, 2622f  
 neuropathology of, 444e-10, 2622  
 prevalence of, 2621  
 treatment of, 444e-7, 2622
- Huntington’s disease–like disorders, 2622
- Hu proteins, 372e-25t
- Hurler disease, 432e-2t, 432e-6, 436e-5f  
 Hurler-Scheie syndrome, 432e-2t, 432e-6
- Hurricanes, 151e-3, 151e-8
- HUS. *See* Hemolytic-uremic syndrome (HUS)
- Hutchinson-Gilford progeria syndrome, 94e-4, 435, 436t
- Hutchinson’s sign, 200
- Hutchinson’s teeth (incisors), 236, 1137
- HV interval, 1474
- Hyaline casts, 62e-11f
- Hyaluronan, 2140
- Hyaluronate lyase, 947f
- Hyaluronic acid, 2226, 2232, 2232t
- Hybrid capture, 150e-6, 150e-7f
- Hybridization, for pathogen identification, 772
- Hydatid disease. *See* Echinococcosis (hydatid disease)
- Hydatidiform mole, 124e-5, 372e-8t, 439.  
*See also* Gestational trophoblastic disease
- Hydralazine  
 adverse effects of, 40, 44, 253t, 363, 1625, 2218t  
 genetic variations in response to, 39t, 40  
 for heart failure, 1512t  
 for hypertension, 1624t, 1625, 2644  
 for hypertensive emergencies, 1627t  
 metabolism of, 34t  
 for preeclampsia, 46
- Hydrocele, 1418, 1418f
- Hydrocephalus  
 adipsic diabetes insipidus in, 304  
 after subarachnoid hemorrhage, 1785  
 coma in, 1776  
 communicating, 174, 175f  
 diagnosis of, 163  
 gait disorders in, 162t, 163  
 in intracranial meningitis, 906  
 normal-pressure, 175f, 2606–2607  
 obstructive  
   in neurocysticercosis, 1430–1431, 1431f, 1432
- Hydrochloric acid therapy, for metabolic alkalosis, 322
- Hydrochlorothiazide, 727t, 1623, 1624t, 2640t
- Hydrocodone, for dyspnea, 62t
- Hydrocortisone  
 for ACTH deficiency, 2260  
 for adrenal insufficiency, 2325–2326  
 for adult hypopituitarism, 2259t  
 for CAH, 2328–2329, 2356  
 for candidiasis, 233  
 for hypercalcemia, 314  
 for hypoadrenal shock, 1751  
 for IBD, 1960  
 for myxedema coma, 2293  
 for septic shock, 1755  
 for thyroid storm, 2297
- Hydrogen chloride, as chemical terrorism agent, 262e-1t
- Hydrogen cyanide. *See* Cyanide poisoning
- Hydrogenotrophic species, in human microbiome, 86e-4
- Hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>), in endothelium, 265e-1
- Hydrogen sulfide exposure/poisoning, 473e-11t, 1692t
- Hydroids, 2738
- Hydromorphone, 62t, 91t, 92
- Hydronephrosis, 1871
- Hydrophobia, 896, 1301, 1302f
- Hydrops, 2081
- Hydrops fetalis  
 clinical features of, 638, 1196  
 diagnosis of, 1196f  
 hemoglobin levels in, 638, 638t  
 IgG antibodies in, 138e-1
- Hydrothorax, 251, 288, 1717
- Hydroureter, 1871
- 5-Hydroxytryptophan, 2623
- Hydroxocobalamin (vitamin B<sub>12A</sub>)  
 for cobalamin deficiency, 648  
 as cyanide antidote, 262e-7–8, 262e-8t, 473e-11t
- β-Hydroxybutyrate, 318, 2434
- 4-Hydroxybutyric aciduria, 434e-2t
- Hydroxychloroquine  
 adverse effects of, 2130t  
   common, 2146f  
   cutaneous, 353, 380  
   myopathy, 462e-20, 462e-20t, 2218t  
   neuropathy, 2686, 2687t  
   ocular, 206  
   serious, 2146t  
 for calcium pyrophosphate deposition disease, 2236  
 for hypercalcemia, 314  
 for infective endocarditis, 823t  
 for malaria prophylaxis, 1383t  
 monitoring during treatment with, 2146t  
 overdose/poisoning with, 473e-13t  
 for porphyria cutanea tarda, 390, 2530  
 for Q fever, 1162  
 for rheumatoid arthritis, 2145, 2146t  
 for sarcoidosis, 2211, 2212t  
 for SLE, 2130t, 2132  
 for Whipple’s disease, 1094
- 2-Hydroxyglutarate (2-HG), 102e-13
- Hydroxykynureninuria, 434e-2t
- 7α-Hydroxylase, 1934
- 11β-Hydroxylase, 434
- 11β-Hydroxylase deficiency  
 clinical features of, 306, 1620, 1620t, 2313, 2357  
 diagnostic markers of, 2328t  
 genetic considerations in, 1620t  
 pathophysiology of, 1621f
- 17α-Hydroxylase (CYP17), 372e-24t
- 17α-Hydroxylase deficiency  
 clinical features of, 306, 1620t, 1621, 2353, 2354t  
 diagnostic markers of, 2328t  
 genetic considerations in, 2353, 2354t  
 genetics of, 1620t  
 hypergonadotropic hypogonadism in, 337  
 hypertension in, 1621  
 pathophysiology of, 1621f
- 21-Hydroxylase (CYP21), 372e-24t
- 21-Hydroxylase antibodies, 2346
- 21-Hydroxylase deficiency  
 classic. *See* Congenital adrenal hyperplasia (CAH)  
 classic simple virilizing, 2355  
 diagnosis of, 333  
 nonclassic, 2355  
 salt-wasting, 2355–2356
- 21-Hydroxylase gene mutations. *See* CYP21A2 (21-hydroxylase gene) mutations
- Hydroxyl radicals, 103e-4
- 3-Hydroxy-3-methylglutaric aciduria, 434e-3t
- 17-Hydroxyprogesterone, 2329, 2760t
- 3β-Hydroxysteroid dehydrogenase deficiency, 2328t, 2357
- 11β-Hydroxysteroid dehydrogenase, 64e-8, 64e-8f, 611, 2312
- 11β-Hydroxysteroid dehydrogenase deficiency. *See* Syndrome of apparent mineralocorticoid excess (SAME)
- 17β-Hydroxysteroid dehydrogenase deficiency, 2353